

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. Any such offer or invitation will be made only in jurisdictions in which it may be legally and validly made. Securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the “SEC”) or an exemption from registration. An effective shelf registration statement on Form F-3, which includes a prospectus (the “**Base Prospectus**”), relating to the public offering of American Depositary Shares (“**ADSs**”) of Legend Biotech Corporation (“**Legend Biotech**”) has been filed by Legend Biotech with the SEC and is effective. Any public offering of ADSs to be made in the United States will be made solely by means of a prospectus supplement to the Base Prospectus that may be obtained, when available, from Legend Biotech and that will contain or incorporate by reference detailed information about the company and management, as well as financial statements of Legend Biotech.*

Neither this announcement nor any content contained herein shall form the basis of any contract or commitment whatsoever.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

COMPLETION OF THE FOLLOW-ON PUBLIC OFFERING OF LEGEND BIOTECH CORPORATION

Reference is made to the announcements of the Company dated 26 July 2022, 27 July 2022 and 28 July 2022 relating to the Follow-On Public Offering of Legend Biotech Corporation (collectively, the “**Previous Announcements**”). Unless otherwise defined, terms used in this announcement shall have the same meanings given to them in the Previous Announcements.

The Board announces that Legend Biotech, a non-wholly owned subsidiary of the Company, whose shares are listed by way of ADSs on the Nasdaq Global Select Market in the United States, informed the Company that the Follow-on Public Offering has been closed on 29 July 2022 (New York time) (after trading hours on 29 July 2022, Hong Kong time). Legend Biotech issued 9,361,000 ADSs in the Follow-on Public Offering, each representing two ordinary shares, at a public offering price of US\$43.00 per ADS. The number of ADSs issued at closing included the underwriters exercising their option to purchase additional 1,221,000 ADSs.

Immediately upon the completion of the Follow-on Public Offering, the shareholding of the Company in Legend Biotech has been diluted and reduced from approximately 56.2% to 53.0%, without taking into account future allotment and issuance of the ESOP Shares and assuming the Legend Warrant has not been exercised. Legend Biotech will continue to be a direct non-wholly owned subsidiary of the Company. The results of operations and financial position of Legend Biotech will continue to be recorded in the Group's consolidated financial statements.

Shareholders and potential investors of the Company should therefore exercise caution when dealing in or investing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 31 July 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*